Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03951259
Recruitment Status : Recruiting
First Posted : May 15, 2019
Last Update Posted : May 23, 2019
Sponsor:
Collaborator:
Jiangsu ZuoYou Medicine Co., Ltd.
Information provided by (Responsible Party):
RenJi Hospital

Brief Summary:
This is a single-center, randomized, double-blind, placebo-controlled, phase 2 study. The purpose of the study is to initially evaluate the safety and efficacy of SM934 combined with steroids compared to placebo in adult subjects with active systemic lupus erythematosus (SLE) over a 12-week period.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Drug: SM934 Drug: Placebos Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of SM934 in Adult Subjects With Active Systemic Lupus Erythematosus
Estimated Study Start Date : May 15, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Arm Intervention/treatment
Experimental: SM934 10mg
SM934 10mg(1 tablet)+Placebo(4 tablets)p.o. qd in combination with steroids
Drug: SM934
In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.

Experimental: SM934 30mg
SM934 10mg(3 tablet)+ Placebo(2 tablets)p.o. qd in combination with steroids
Drug: SM934
In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.

Experimental: SM934 50mg
SM934 10mg(5 tablet)p.o. qd in combination with steroids
Drug: SM934
In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.

Placebo Comparator: Placebo
Placebo(5 tablets)p.o. qd in combination with steroids
Drug: Placebos
The placebo pills are made identical to the investigating SM934 in appearance.




Primary Outcome Measures :
  1. Percentage of Subjects with Lupus Low Disease Activity Score (LLDAS) in each group [ Time Frame: Week 12 ]

    LLDAS is defined as meeting the following criteria:

    1. SLEDAI-2K ≤4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis), and no reported fever, hemolytic anemia, or gastrointestinal activity)
    2. No new disease activity compared with the previous assessment (no new British isles lupus assessment group (BILAG) A domain score or no more than 1 new BILAG B domain score)
    3. PGA ≤1 on a 0-3 scale visual visual analogue scale (VAS)
    4. A current prednisone (or equivalent) dose of ≤7.5 mg daily
    5. Well-tolerated standard maintenance doses of permitted immunosuppressive drugs

  2. Percentage of Subjects with Systemic Lupus Erythematosus Responder Index - 4 (SRI-4) response in each group [ Time Frame: Week 12 ]

    SRI-4 response is defined as:

    1. ≥ 4-point reduction from baseline in SLEDAI-2K score
    2. No new BILAG A and no more than 1 new BILAG B domain score
    3. No worsening from baseline in the PGA (<10% worsening from baseline).

  3. Percentage of Subjects with Treatment-Emergent Adverse Events (TEAEs) in each group [ Time Frame: Baseline through Week 13 ]
    Percentage of Subjects with TEAEs in each group


Secondary Outcome Measures :
  1. Percentage change of SLEDAI-2000 and Physician Global Assessment (PGA) from baseline in each group [ Time Frame: Week 12 ]
    Percentage change of SLEDAI-2000 and PGA from baseline in each group

  2. Percentage of Subjects with 30% improvement in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score in each group [ Time Frame: Week 12 ]
    Percentage of subjects who have at least 30% improvement in CLASI score compared to baseline.

  3. Change of SLICC/ACR from baseline [ Time Frame: Week 12 ]
    Change of SLICC/ACR score from baseline

  4. Percentage of subjects and number of days with steroids dose equal or less to prednisone 7.5mg per day [ Time Frame: Week 12 ]
    Percentage of subjects and number of days with steroids dose equal or less to prednisone 7.5mg per day

  5. Percentage of subjects with Proteinuria < 0.5g/24h in each group [ Time Frame: Week 12 ]
    Percentage of subjects with 24hour urine protein level less than 0.5g in each group

  6. Percentage change of complement 3 (C3) and complement 4 (C4) from baseline in each group [ Time Frame: Week 12 ]
    Percentage change of complement 3 (C3) and complement 4 (C4) from baseline in each group

  7. Percentage change of anti-dsDNA level from baseline in each group [ Time Frame: Week 12 ]
    Percentage change of anti-dsDNA level from baseline in each group

  8. Time to SLE flare and Percentage of subjects with SLE flare [ Time Frame: Baseline through week 12 ]
    SLE flare is defined as: Compared to baseline, one new BILAG A or more than 1 new BILAG B domain score. Time to SLE flare is defined as the date of SLE flare minus the date of treatment initiation plus one.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 18 to 70;
  • Have a clinical diagnosis of SLE according to SLICC-2012 classification criteria;
  • Have active SLE with SLEDAI-2k ≥ 6;
  • Have positive anti-nuclear antibody (ANA) test results;
  • Are on a stable steroids treatment (equals to prednison more than 7.5mg daily but no more than 0.5mg/kg/d) for SLE for at least 30 days prior to first dose of study agent;
  • Females of childbearing age are willing to use appropriate contraception;
  • Are voluntary to to provide and sign voluntary informed consent is given;

Exclusion Criteria:

  • Have any unstable or progressive manifestation of SLE, including but not limited to Central nervous system (CNS) involvement, transverse myelitis, systemic vasculitis, vasculitis with GI involvement, severe or rapidly progressive lupus nephritis, lupus nephritis with proteinuria > 3g/24h, pulmonary hemorrhage, myocarditis;
  • Have abnormal liver function test or renal function test: Alanine aminotransferase(ALT)or aspartate aminotransferase (AST) >2 upper limit of normal (ULN); Gamma-glutamyl transferase (GGT) >1.5 ULN; Creatinine or Blood urea nitrogen (BUN) >1.5 ULN;
  • Have a history of acute myocardiac infarction, unstable angina, severe arrhythmias within 6 months prior to first dose of study agent;
  • Have any major illness/condition or evidence of an unstable clinical condition not due to SLE (eg, cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, psychiatric), which, in the Investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study;
  • Have any acute or chronic infectious disease, which requires medical intervention;
  • Have a history of cancer within the last 5 years, except for adequately treated skin cancer, or carcinoma in situ of the uterine cervix;
  • Have a planned surgical procedure;
  • Have received a biologic investigational agent in the past one year;
  • Have received the following treatment within 30 days prior to first dose of study agent: live vaccine; change of glucocorticoids dose; IV, intra-muscular (IM), intra-articular (IA) administration of glucocorticoids; other immunosuppressants/immunomodulators; anti-malarial drugs; traditional medicines which has proved to be effective in SLE;
  • Have had a major organ transplant;
  • Have a history of HIV, or test positive at screening for HIV;
  • Test positive for Hepatitis B virus (HBV)-DNA or Hepatitis C virus (HCV)-RNA;
  • Have or have had a substance abuse (drug, alcohol) problem in the past one year;
  • Are currently using or planned to use estrogen-containing contraceptive methods;
  • Have enrolled in an investigational study within 3 months prior to first dose of study agent;
  • Investigator considers candidates not appropriating for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03951259


Contacts
Layout table for location contacts
Contact: Nan Shen, MD & PhD +86-21-63260477 nanshensibs@gmail.com
Contact: Huihua Ding, MD +86-21-53882280 dinghuihua@outlook.com

Locations
Layout table for location information
China, Shanghai
Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University Recruiting
Shanghai, Shanghai, China, 200001
Contact: Nan Shen, MD & PhD    +86-21-63260477    nanshensibs@gmail.com   
Contact: Huihua Ding, MD    +86-21-53882280    dinghuihua@outlook.com   
Principal Investigator: Nan Shen, MD & PhD         
Sub-Investigator: Qiang Guo, MD & PhD         
Sub-Investigator: Min Dai, MD         
Sub-Investigator: Huihua Ding, MD         
Sponsors and Collaborators
RenJi Hospital
Jiangsu ZuoYou Medicine Co., Ltd.

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: RenJi Hospital
ClinicalTrials.gov Identifier: NCT03951259     History of Changes
Other Study ID Numbers: SM934
First Posted: May 15, 2019    Key Record Dates
Last Update Posted: May 23, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Artemisinins
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents